$CGON News

CG Oncology: A Second-Mover Advantage In Bladder-Sparing Therapy

How Investors May Respond To CG Oncology (CGON) Hiring a CCO Before Potential Bladder Cancer Launch

CG Oncology Appoints Proven Biopharmaceutical Commercial Leader Isabel Kalofonos as Chief Commercial Officer

CG Oncology, Inc. (CGON) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

CG Oncology (CGON) Stock Looks Fully Priced After A 160% Run

CG Oncology to Present at Upcoming Investor Conferences in September

CG Oncology (NASDAQ:CGON) Flaunts a Perfect Technical Breakout Setup

CG Oncology: Circling Back After Huge Rally

RBC Capital Maintains Outperform on CG Oncology, Lowers Price Target to $79

Piper Sandler Maintains Overweight on CG Oncology, Raises Price Target to $85

Truist Securities Maintains Buy on CG Oncology, Raises Price Target to $85

CG Oncology Reports Second Quarter 2026 Financial Results and Provides Business Updates

CG Oncology Q2 EPS $(0.90) Misses $(0.67) Estimate, Sales $1.157M Beat $360.417K Estimate

CG Oncology Announces Publication of Pivotal Phase 3 BOND-003 Cohort C Study Results in The Lancet Oncology

CG Oncology: Priced To Perfection On Future Pipeline Success

ANI Pharmaceuticals Announces Intent to Appeal Rulings in CG Oncology Matter

CG Oncology Eyes Bladder Cancer Breakthrough With Phase 3 Data, Q4 Filing Ahead

CG Oncology, Inc. (CGON) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

CG Oncology Touts Cretostimogene Data, BLA Progress in Bladder Cancer Push

Did CG Oncology’s Leadership Consolidation Around CEO Kuan Just Shift CGON’s Commercialization Narrative?